FDA Approves Varenicline Tartrate ANDA219382 by Somerset Therap LLC
The FDA has approved the ANDA for Varenicline Tartrate submitted by Somerset Therap LLC.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Smoking Cessation / Nicotine Receptor Agonist
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Varenicline Tartrate by Somerset Therap LLC represents a significant development in the smoking cessation market, potentially altering competitive dynamics. Portfolio teams must evaluate how this approval impacts existing products and market strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and initial sales performance of Varenicline Tartrate.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.